Prediction: Eli Lilly Will Reach $1,200 in 2026

Eli Lilly (NYSE: LLY) doesn't request a cleanable twelvemonth to scope $1,200 successful 2026. It does, however, request to support its continued dominance successful the rapidly increasing marketplace for obesity and diabetes drugs -- and that's precisely however things are playing out. Let's spot wherefore investors should stay upbeat connected Eli Lilly.

Extraordinary maturation continues

Lilly's GLP-1 franchise, led by Mounjaro and Zepbound, continues to make bonzer growth. During the archetypal 4th of 2026, Lilly reported astir $13 cardinal successful combined quarterly gross from the 2 drugs. That's not trivial, particularly erstwhile you see that the bull lawsuit for Lilly progressively revolves astir the aboriginal size of the obesity market.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

Recent medicine information suggest that Lilly present controls astir 60% of the U.S. GLP-1 market,a singular accomplishment considering Novo Nordisk's aboriginal pb with Ozempic and Wegovy.

The adjacent signifier of maturation whitethorn travel from extracurricular the U.S.

While the marketplace has agelong been focused chiefly connected home medicine trends, planetary markets could yet go conscionable arsenic important. Obesity rates proceed rising globally, and galore countries are lone opening to grow entree to GLP-1 therapies.

Mounjaro has already launched crossed overmuch of Europe, the Middle East, Asia, and Latin America. International income of Lilly's incretin medicines (drugs that assistance patients suffer value and power humor sugar) person been increasing importantly faster than the broader pharmaceutical market, too. In Q1 2026, gross extracurricular the U.S. accrued 81% twelvemonth implicit twelvemonth to $7.7 billion.

Europe, for instance, remains 1 of the biggest opportunities. Germany could soon go 1 of Lilly's fastest-growing obesity markets, and France precocious became the archetypal large E.U. state to o.k. reimbursement for obesity treatments. Meanwhile, request continues increasing successful China, Japan, and respective Middle Eastern countries, wherever obesity and diabetes rates stay elevated.

Still, to warrant a $1,200 stock price, Lilly apt needs Mounjaro and Zepbound to present monolithic gross extracurricular the U.S. We're talking astir $60 cardinal to $70 cardinal a year.

Consider the mathematics

If Lilly tin proceed taking marketplace share, grow internationally, and support beardown pricing power, reaching $60 cardinal to $70 cardinal successful yearly gross implicit the adjacent twelvemonth isn't an unrealistic target.